Acceleron

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023

Retrieved on: 
Tuesday, February 27, 2024
Conference call, Cohort, Research, GSK, Fulcrum, Acceleron, REACH, SCD, Conference, Therapy, Collaboration, FSHD, Webcast, Patient, Disease, Losmapimod, Pharmaceutical industry

CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (“Fulcrum”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today reported financial results for the fourth quarter and full year of 2023 as well as an update to the business.

Key Points: 
  • Collaboration Revenue: Collaboration revenue was $0.9 million for the fourth quarter of 2023 as compared to $0.7 million for the fourth quarter of 2022.
  • G&A Expenses: General and administrative expenses were $9.9 million for the fourth quarter of 2023 as compared to $10.1 million for the fourth quarter of 2022.
  • Net Loss: Net loss was $24.8 million for the fourth quarter of 2023 as compared to $26.1 million for the fourth quarter of 2022.
  • ET to review the fourth quarter and full year 2023 recent business highlights and financial results.

Day One Announces Two New Appointments to Board of Directors

Retrieved on: 
Wednesday, January 17, 2024
Patient, Therapy, Medical college, Acceleron, Medical director, Hematology, Cancer, Microbiology, Gilead Sciences, Acquisition, Bayer, Cardiology, Neurology, AbbVie, Merck, Growth, Pharmaceutical industry

“We are excited to welcome Habib and Bill to our Board during this pivotal phase of our growth,” said Jeremy Bender, Ph.D., chief executive officer of Day One.

Key Points: 
  • “We are excited to welcome Habib and Bill to our Board during this pivotal phase of our growth,” said Jeremy Bender, Ph.D., chief executive officer of Day One.
  • “It’s a privilege to join the Board of Day One at such an important time,” said Habib Dable.
  • He currently sits on the Board of Directors for Pionyr Immunotherapeutics and Tizona Therapeutics, Inc., and the Oncology Advisory Board for Bryologyx.
  • I am grateful to join the Day One Board with my colleague Habib, and look forward to contributing to the evolution of the company.”

Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors

Retrieved on: 
Wednesday, November 29, 2023
Research, Legal, Finance, Clinical Trials, Professional Services, Biotechnology, General Health, Pharmaceutical, Health, Science, Merck & Co., Acquisition, Ropes & Gray, General counsel, GOSS, Entrepreneurship, Executive, Gossamer, Pulmonary hypertension, Doctor of Philosophy, Bristol Myers Squibb, Orthostatic hypertension, Merck, Stanford University, Harvard College, Acceleron Pharma, Massachusetts Institute of Technology, Harvard Law School, Corporate development, PAH, Biology, Pharmaceutical industry, Management, Acceleron

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced the appointment of John Quisel, J.D., Ph.D., President and CEO of Disc Medicine, to its Board of Directors.

Key Points: 
  • Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced the appointment of John Quisel, J.D., Ph.D., President and CEO of Disc Medicine, to its Board of Directors.
  • “Today, we are thrilled to announce that Dr. John Quisel has joined the Gossamer team," said Faheem Hasnain, Chairman, Co-Founder and CEO of Gossamer Bio.
  • We are confident that Dr. Quisel’s appointment enhances our ability to get seralutinib to patients.”
    “I am honored to join Gossamer’s Board at this pivotal moment for the Company,” said Dr. Quisel.
  • During his tenure, Dr. Quisel also served in various roles, including Senior Vice President of Corporate Development and General Counsel.

Aerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights

Retrieved on: 
Monday, August 14, 2023
PAH, ATS, Clinical trial, Merck & Co., American Thoracic Society, Sale, ATM, International Conference on Nuclear Disarmament, Oslo, 2008, Patient, Merck, R, Research, Orthostatic hypertension, Therapy, Conference, Compensated emancipation, Pharmaceutical industry, Bank, Cryptocurrency, G&A, Acceleron

We expect to report topline data from the Phase 2b portion of IMPAHCT in the second quarter of 2024.

Key Points: 
  • We expect to report topline data from the Phase 2b portion of IMPAHCT in the second quarter of 2024.
  • R&D expenses: Research and development (R&D) expenses for the second quarter ended June 30, 2023 were $16.0 million as compared to $8.4 million for the second quarter ended June 30, 2022.
  • G&A expenses: General and administrative (G&A) expenses for the second quarter ended June 30, 2023 were $4.3 million as compared to $3.9 million for the second quarter ended June 30, 2022.
  • Net loss: Net loss for the second quarter ended June 30, 2023 was $19.0 million as compared to $12.0 million for the second quarter ended June 30, 2022.

Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors

Retrieved on: 
Tuesday, July 11, 2023
BIO, Chairperson, PAH, Bayer, ARCH Venture Partners, Merck & Co., Sale, Aerovent, Ophthalmology, Patient, Neurology, Merck, Orthostatic hypertension, Therapy, Biotechnology Innovation Organization, Pharmaceutical industry, Nursing, Acceleron

"We are excited to welcome Habib to Aerovate’s Board of Directors.

Key Points: 
  • "We are excited to welcome Habib to Aerovate’s Board of Directors.
  • Mr. Dable is currently a part-time Venture Partner at RA Capital Management, L.P., and previously served on the Board of Directors of the Biotechnology Innovation Organization (BIO).
  • “The appointment of Mr. Dable further enhances the diverse expertise of our Board as Aerovate continues to advance AV-101 through the clinic,” said Mark Iwicki, Chair of the Board.
  • “We look forward to having Habib on the Board as we support the company’s ongoing growth.”
    “I am honored to join the Board during a pivotal time for the company,” said Mr. Dable.

Dianthus Therapeutics Appoints Adam Veness, Esq., as General Counsel

Retrieved on: 
Tuesday, June 20, 2023
Intellectual property, Therapy, Senior, General counsel, Veness, Science, Tulane University, Boston University School of Law, Philosophy, Acquisition, Patient, Autoimmune disease, Executive Committee, Acceleron Pharma, Growth, Merck, Dianthus, Popular Executive Committee of Valencia, Acceleron, Management

NEW YORK and WALTHAM, Mass., June 20, 2023 /PRNewswire/ -- Dianthus Therapeutics, a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, today announced the appointment of Adam Veness, Esq., as General Counsel. Joining Dianthus most recently from Cyteir Therapeutics, Veness spent much of his career as Senior Vice President, General Counsel and Secretary at Acceleron Pharma Inc. prior to the acquisition by Merck in November 2021. During his tenure at Acceleron, Veness gained experience in roles of increasing responsibility where he served on the Executive Committee responsible for company strategy, and he led all aspects of global legal and compliance, including capital markets and SEC reporting obligations, corporate governance, contracts, intellectual property, employment matters, and data privacy.

Key Points: 
  • Joining Dianthus most recently from Cyteir Therapeutics, Veness spent much of his career as Senior Vice President, General Counsel and Secretary at Acceleron Pharma Inc. prior to the acquisition by Merck in November 2021.
  • "We are excited to welcome Adam to the Dianthus team at such a pivotal time for the company," said Marino Garcia, President and Chief Executive Officer of Dianthus Therapeutics.
  • I am looking forward to working with Adam and to his contributions as we continue to build an exciting biotech company."
  • "I am thrilled to join Dianthus as the company embarks on this exciting chapter of growth," said Adam Veness, Esq., General Counsel of Dianthus Therapeutics.

Global Pulmonary Arterial Hypertension (PAH) Industry Research 2023 - ResearchAndMarkets.com

Retrieved on: 
Friday, June 16, 2023
Health, Pharmaceutical, Online, Exercise, Drug, Pharmacy technician, Prevalence, PAH, Hospital, COVID-19, Breakthrough therapy, MRK, Quality of life, Endothelin receptor antagonist, Artery, Inhalation, Eras, EMA, Prostacyclin, Market, Organization, Administration, NO, Acquisition, HIV disease progression rates, Patient, Hemodynamics, Iloprost, Pulmonary artery, Distribution, Route of administration, European Medicines Agency, Merck, Ageing, Orthostatic hypertension, FDA, Generic, Safety, Pulmonary hypertension, Disease, Pharmaceutical industry, Health care, Acceleron

The global pulmonary arterial hypertension market was valued at US$8.18 billion in 2022.

Key Points: 
  • The global pulmonary arterial hypertension market was valued at US$8.18 billion in 2022.
  • Pulmonary arterial hypertension (PAH) is a rare and progressive disorder characterized by elevated blood pressure of more than 25mmHg in the arteries of the lungs, also known as the pulmonary artery.
  • On the other hand, therapeutic options for pulmonary arterial hypertension (PAH) have increased over the last decades.
  • The global pulmonary arterial hypertension market is moderately concentrated.

Aerami Therapeutics Appoints Lisa Yañez as Chief Executive Officer

Retrieved on: 
Wednesday, December 21, 2022
City of London Finance Committee, Investigational New Drug, Biotechnology, Food, Pulmonary hypertension, Therapy, MD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Merck, United Therapeutics, GSK, Acceleron Pharma, University, FDA, American Board of Nuclear Medicine, Committee on Finance, Acceleron, PAH, Pharmaceutical industry, Genentech

DURHAM, N.C., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Aerami Therapeutics Holdings, Inc (“Aerami”), a clinical-stage biopharmaceutical company dedicated to breathing life into the treatment of serious cardiopulmonary and cardiometabolic conditions, today announced the appointment of Lisa Yañez as chief executive officer, effective January 1, 2023. As part of a planned leadership transition, Steve Thornton will retire as CEO at the end of the year but remain on the Board of Directors and assume the Chairmanship of the Finance Committee.

Key Points: 
  • DURHAM, N.C., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Aerami Therapeutics Holdings, Inc (“Aerami”), a clinical-stage biopharmaceutical company dedicated to breathing life into the treatment of serious cardiopulmonary and cardiometabolic conditions, today announced the appointment of Lisa Yañez as chief executive officer, effective January 1, 2023.
  • Ms. Yañez has more than 25 years of leadership experience at leading pharmaceutical and biotechnology companies, including Merck, Genentech, GSK, and most recently, United Therapeutics and Acceleron Pharma.
  • At United Therapeutics, Ms. Yañez led the multi-billion-dollar PAH franchise that includes five of the fifteen currently FDA-approved therapies for PAH.
  • “I look forward to continuing to work closely with her and her team at Aerami Therapeutics as they further develop AER-901 to address high unmet need for new therapeutic options.”

PepGen Appoints Habib Dable to Board of Directors

Retrieved on: 
Thursday, September 22, 2022
Peptide, Therapy, Sale, Business administration, Disease, Norwest Venture Partners, Growth, Bayer, Private Securities Litigation Reform Act, Industry, University of New Brunswick, Form 10-Q, Patient, CEO, EDO, RA, MBA, Technology, BIO, Acceleron Pharma, Board of directors, Sustainability Accounting Standards Board, Biotechnology Innovation Organization, Ophthalmology, Board, Neurology, Form, Merck & Co., Research, GLOBE, SEC, University, Merck, Duchenne muscular dystrophy, Pharmaceutical industry, Duchenne, Director, Acceleron

BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (PepGen), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Habib Joseph Dable to its Board of Directors.

Key Points: 
  • BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (PepGen), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Habib Joseph Dable to its Board of Directors.
  • Mr. Dable is also a former Independent Director of Millendo Therapeutics and previously served on the Board of Directors of the Biotechnology Innovation Organization (BIO).
  • I am delighted to join the Board of Directors and look forward to working with James and the Board to advance PepGen as a leading company developing potentially transformative therapies for people living with these devastating diseases.
  • PepGen explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Blueprint Medicines Appoints Habib Dable to its Board of Directors

Retrieved on: 
Thursday, June 23, 2022
Organization, SEC, Patient, Precision medicine, University, Multimedia, Acquisition, Science, NASDAQ, Annual report, Safety, Security (finance), COVID-19, Degenerative disease, Bayer, Private Securities Litigation Reform Act, Lung cancer, Acceleron Pharma, BIO, Research, Patent, Neurology, Risk, Cardiology, Merck, Biotechnology, CEO, Leadership, BPMC, University of New Brunswick, Cancer, Board, Biotechnology Innovation Organization, Disease, U.S. Securities and Exchange Commission, View, Twitter, LinkedIn, Goal, Hematology, Growth, Management, Pharmaceutical industry, Marketing, Acceleron, Blueprint, Ophthalmology

CAMBRIDGE, Mass., June 23, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of Habib Dable to its board of directors.

Key Points: 
  • CAMBRIDGE, Mass., June 23, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of Habib Dable to its board of directors.
  • "Blueprint Medicines has an impressive track record for a company of its size and age; even more impressive are the potential opportunities that lie ahead across development and commercialization," said Mr. Dable.
  • Mr. Dable joins Blueprint Medicines with significant leadership, growth and commercial experience gained during nearly 30 years in the biopharmaceutical industry.
  • Blueprint Medicines, AYVAKIT, AYVAKYT, GAVRETO and associated logos are trademarks of Blueprint Medicines Corporation.